Impact of maternal HIV medication on child fat and bone development
Official title: Impact of maternal integrase inhibitor use on offspring fat and bone development
Funded at Rush University Medical Center · NIH-11427217 · Data updated 2026-11-12
This project studies how a pregnancy exposure to a specific HIV medicine (InSTI-based ART) might affect a child’s fat tissue and bone growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rush University Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | July 2, 2026 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,787,803 |
| NIH project number | 1R01HD122687-01 |
| Project ID | NIH-11427217 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children aged from birth to adolescence who were exposed to integrase strand transfer inhibitor–based ART in utero.
✕Less likely to help
Children not exposed to InSTI-based ART during gestation or without HIV exposure may not benefit from this study.
What this research studies
If your child was exposed to HIV medications in the womb, this study will look for clues about how those drugs could influence fat and bone development as they grow. Researchers will use patient data and animal models to explore the biological pathways that could link in utero exposure to later changes in body composition and bone health. The goal is to understand mechanisms so doctors can better manage future pregnancies and monitor affected children. This work builds on prior findings that InSTI exposure during pregnancy may have lasting effects on weight and bone length.
Why it matters
Potential benefit: Findings could guide safer ART choices during pregnancy and improve monitoring for children exposed to these medicines.
How similar studies have gone: Preclinical models have shown weight and bone-length changes with InSTI exposure, suggesting potential relevance to humans but translational confirmation is needed.
Where this research is happening
-
Rush University Medical Center
Chicago, United States Active
Researchers
- Principal investigator: Ross, Ryan Dee — Rush University Medical Center
- Study coordinator: Ross, Ryan Dee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.